New drug combo targets advanced cervical cancer
NCT ID NCT07542717
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two experimental drugs, MRG003 and QL1706, together in people with cervical cancer that has returned or spread and no longer responds to standard chemotherapy. About 41 adults will receive the combination to see if it shrinks tumors. The goal is to control the disease, not cure it.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT OR METASTATIC CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Hormone-Blocking drug boost chemo against cervical cancer?
- Could a Two-Drug combo outsmart advanced cervical cancer?
- Immune cells from your own tumor could fight cervical cancer
- Triple-Drug cocktail takes on recurrent gynecologic cancers
- New hope for Hard-to-Treat cervical cancer? drug trial targets HER2
- New drug duo takes on multiple cancers in Mid-Stage trial